# Sermorelin Study References: GHRH(1-29) Citations with DOIs and PMIDs

> Sermorelin study references — the full citation list behind this digest, with DOIs and PubMed links for the GHRH(1-29) pediatric, adult, pharmacokinetic, safety, and cognition trials.

Every figure on this site resolves here — author, year, DOI, and PubMed link.

## The source register

These are the peer-reviewed sources behind every quantitative claim in this digest — the pediatric and adult GHRH(1-29) trials, the pharmacokinetic and safety studies, the GH-axis reviews, and the GHRH-analog cognition trial. Each numbered citation matches the inline markers used across the [sermorelin research](/research), [sermorelin side effects](/side-effects), [sermorelin vs ipamorelin](/vs-ipamorelin), and [research doses of sermorelin](/dosage) pages. Full citations with DOIs and PubMed identifiers are listed below.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Vijayakumar A, et al. Role of pulsatile growth hormone (GH) secretion in the regulation of lipolysis in fasting humans. Clin Diabetes Endocrinol. 2022;8(1):1. https://pubmed.ncbi.nlm.nih.gov/35101148/
[7] Muller EE, Locatelli V, Cocchi D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. https://pubmed.ncbi.nlm.nih.gov/9861545/
[8] Vance ML, Kaiser DL, Evans WS, et al. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab. 1986;63(4):872-878. https://pubmed.ncbi.nlm.nih.gov/3091629/
[9] Falutz J, et al. (tesamorelin visceral-fat trial). Discussed in: Granata R, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[10] Munafo A, Nguyen TX, Papasouliotis O, et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects. Eur J Endocrinol. 2005;153:249-56. https://pubmed.ncbi.nlm.nih.gov/16061831/
[11] Vance ML, Kaiser DL, Evans WS, et al. The effect of pulsatile administration, continuous infusion, and diurnal variation on the GH response to GH-releasing hormone in normal men (pulsatile-secretion basis). J Clin Endocrinol Metab. 1986;63(4):872-878. https://pubmed.ncbi.nlm.nih.gov/3091629/
[12] Schier T, Guldner J, Colla M, et al. Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administration. J Neuroendocrinol. 1997;9(3):201-205. https://pubmed.ncbi.nlm.nih.gov/9089471/
[13] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of GHRH(1-29)-NH2 in healthy subjects (rapid plasma clearance; basis for longer-acting analogs). Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[14] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[15] Granata R, et al. Growth hormone-releasing hormone and its analogues in health and disease (GH/IGF-1 axis and sarcopenia context). Nat Rev Endocrinol. 2025. https://pubmed.ncbi.nlm.nih.gov/39537825/
[16] Friedman SD, et al. GHRH effects on brain GABA in mild cognitive impairment and healthy aging. (Reported with the GHRH cognition trial program.) Arch Neurol. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
[17] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. (NCT00257712). https://pubmed.ncbi.nlm.nih.gov/22869065/
[18] Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl. 1993;388:32-5; discussion 36. https://pubmed.ncbi.nlm.nih.gov/8329830/

---

A dark, signal-first readout of the sermorelin record — every GHRH(1-29) figure logged to its study and the honest long-term gaps lit beside it, with no clinic behind the console and nothing here compounded, prescribed, or sold.